Dr. Wafik S. El-Deiry, Chair of the Win Consortium in Precision Oncology, Director of the Cancer Center at Brown University, and Associate Dean at the Warren Alpert Medical School, joins BGICC 2026 to discuss the future of precision oncology and its role in improving global cancer care. He highlights the importance of collaboration, equity, and access to molecular testing and targeted therapies, particularly in the MENA region and Africa. He explains how the Win Consortium uses molecular tumor boards, clinical trials, and innovative targeted therapy combinations to tailor treatment to individual patients’ tumors. He also shares the promise of digital pathology and AI in expanding access to detailed molecular profiling and actionable targets worldwide. Dr. Wafik S. El-Deiry reflects on his research contributions, including the FDA approval of Dordaviprone for recurrent diffuse gliomas with H3 K27M mutations, emphasizing the potential of novel therapies and combinations to advance cancer care globally.
Please see video below: